New anti-obesity drugs for FDA approval

Obesity is one of the most common diseases in the world and is defined as a condition in which there is an excessive amount of body fat. Obesity represents a risk of further health impairment.

Two new obesity drugs have been produced and are waiting for the approval by the FDA. They are called Acomplia and Alli. Acomplia is manufactured by Sanofi-Aventis and it works by controlling the brain signals, which trigger signals for appetite control and stimulation to eat more.
Alli is produced by GlaxoSmithKline. This obesity drug controls the body’s fat absorption and, in that way, leads to weight loss. Alli is available in drug market under the trade name of xenical. Trials on this drug have found that it doen’t cause any adverse effects and that reduces 12.4 pounds of weight on an average six months of the drug intake.

Big consumer demands are estimated for these drugs if they get approved as well as high profits for their manufacturers.